Alertmeipp, It was only somewhat logical -- Neurology didn't issue a ruling on chronic dosing. And there were many other red flags that we ignored - the sudden financing, the amazingly bad terms of the financing, the sudden emergence of RD as an 'acute" fallback option, the ongoing CYA mentality at the FDA, especially toward ADHD drugs, etc. I had switched off my antenna and went with what I hoped would happen. Wishful thinking at its worst.
If we were truly logical, we wouldn't be long in a sector where 95% of all products fail, we'd be shorting these stocks like the hedge funds do.
Market Data 
Markets 
AI
